Europe
GENFIT today announces some key leadership changes to accompany GENFIT into the next stage of its development and its evolution from an R&D biotechnology company to a fully-integrated biopharmaceutical company.
Completion of enrollment of approx. 1000-patient study cohort for Phase 3 RESOLVE-IT study, on the basis of which conditional marketing approval for elafibranor in NASH could be obtained in 2020. Interim data readout expected by end of 2019.
TCT18: New Five-Year Data with CoreValve TAVR System Suggests Durability Over Time, While Complete Results from the SURTAVI Trial Show Benefits of TAVR in Intermediate Risk Patients
Horizon Discovery Group plc, announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.
Oculis, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings extensive clinical experience.
Karolinska Development’s portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm.
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), announces that the Company will present on 26 September at the 26th Annual Meeting of the European Orthopaedic Research Society (EORS), in Galway, Ireland.
Bluechiip Ltd (ASX:BCT) provides the Company’s Annual Report to shareholders.
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
Merck and Co., like many large corporations, has a mandatory retirement age of 65 for its chief executive officer. Today the company announced its board of directors and rescinded the policy to allow its current chief executive officer, Kenneth C. Frazier, stay on beyond his 65th birthday in December 2019.
PRESS RELEASES